
OMRE



JUN-06-01

IN THE LINITED STATES PATENT AND TRADEMARK OFFICE

olicants:

Eugen Koren and Mima Koscec

Serial No:

08/765,324

Art Unit:

1645

Filed:

December 24, 1996

Examiner:

P. Duffy

For:

ANTIBODIES TO LIPOPROTEINS AND APOLIPOPROTEINS

AND METHODS OF USE THEREOF

Assistant Commissioner for Patents Washington, D. C. 20231

POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST AND REVOCATION OF PRIOR POWERS

Sir:

As owner of the entire interest of the above-identified patent application, all powers of attorney previously given are hereby revoked and the following attorneys and agents are hereby appointed to prosecute and transact all business in the Patent and Trademark Office connected therewith:

> Potrea L. Pabst Zhaoyang Li


Registration No. 31,284 Registration No. 46,872

Please send all correspondence relating to the above-identified patent application to:

Patrea L. Pabst HOLLAND & KNIGHT LLP One Atlantic Center 1201 West Perchtree Street, Suite 2000 Atlanta, Georgia 30309-3400

(404) 817-8473 - Telephone (404) 817-8588 - Telefax

MAY. 10 '2001 17:01 '



U.S.S.N.08/765,324
Piled December 24, 1996
Power of Attorney by Assignee of Interest and Rayseather of Prior Powers

The undersigned signatory (whose titls is supplied below) is empowered to act on behalf of the assignee identified below, and has reviewed all the documents in the chain of title of the patent application and, to the best of undersigned's knowledge and belief, title is in the assignee.

OKLAHOMA MEDICAL RESEARCH FOUNDA'TION

Dv.

Name:

Title

who te harlogy

Date:

ATL1 #396730 vi

30'2001 17:01 '



Approved for use through 05/30/2000, OMB 056 Patent and Theorem Office; U.S. DEPARTMENT OF COMM

Under the Paperred's Reduction Act of 1999, no persons are required to a called on a information unless it displays a yell QMB control number of the paperred for the paperred f STATEMENT UNDER 37 CFR 3,73(b) Applicant/Patent/Owner: Eugen Koren and Mirna Koscac Filed/losue Date: December 24, 1866 Application No./Patent No.: 08/765,324 Entitled: ANTIBODIES TO LIPOPROTEINS AND APOLIPOPROTEINS AND METHODS OF USE Oklahoma Medical Research Foundation , a University (Type of Assignee, a.g., concording, partnership, university, government equitor, etc.) (Name of Assignee) states that it is: 1. X the assignee of the entire right, little, and interest; of 2. an assignee of an undivided part interest. in the patent application/patent identified above by virtue of either: A [x] An assignment from the invehtor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel 5378 . Frame 0434 , or for which a copy thereof is attached. OR B. [] A chein of title from the inventor(a), of the patent application/potentidentified above, to the current essigned as shown below. To:_. 1. from: The document was regarded in the Patent and Trademark Office at ____, Frame _____, or for which a copy thereof is attached. 2. From: To: The document was recorded in the Pateni and Trademark Office at _____, Frame _____, or for which a copy thereof is attached. Reel 3. From: The document was recorded in the Petent and Trademark Office at Real ______, Frame _____, or for which a copy thereof is attached. [] Additional documents in the chain of title are listed on a supplemental sheet. [] Copies of assignments or other documents in the chain of title are attached. INOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be automitted to Assignment Division in socordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the PTO. See MPEP 302-302.8] The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee

Burden Hour Statement: This form is assimited to take 0.2 hours to complete. Time will very depending upon the needs of the individual case, Aity comments on the amiliar of time you are regarded to complete this form should be sent to the Chief information Officer, Patient and Trademark Office, Washington, DC 20231. DO NOT SEND FEEG OR COMPLETED FORMS TO THIS ADDRESS, GEND TO, Assistant Commissioner for Patients, Washington, DC 20231.

Title